Beacon Investment Advisory Services, Inc. Seagen Inc. Transaction History

Beacon Investment Advisory Services, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	SELL	$191.51 - $216.16 $75,646 - $85,383	-395 Reduced 2.39%	16,108 $3.42 Million
Q2 2023 Jul 21, 2023	SELL	$187.64 - $206.25 $36,589 - $40,218	-195 Reduced 1.17%	16,503 $3.18 Million
Q1 2023 May 04, 2023	BUY	$127.59 - $203.08 $718,459 - $1.14 Million	5,631 Added 50.88%	16,698 $3.38 Million
Q4 2022 Jan 13, 2023	SELL	$117.37 - $139.17 $3,521 - $4,175	-30 Reduced 0.27%	11,067 $0
Q3 2022 Oct 20, 2022	SELL	$135.27 - $180.11 $2,299 - $3,061	-17 Reduced 0.15%	11,097 $1.52 Million
Q2 2022 Jul 21, 2022	SELL	$108.81 - $179.33 $761 - $1,255	-7 Reduced 0.06%	11,114 $1.97 Million
Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $91,860 - $121,228	-768 Reduced 6.46%	11,121 $1.6 Million
Q4 2021 Feb 04, 2022	SELL	$142.57 - $190.86 $51,467 - $68,900	-361 Reduced 2.95%	11,889 $1.84 Million
Q3 2021 Nov 09, 2021	BUY	$142.45 - $169.82 $65,242 - $77,777	458 Added 3.88%	12,250 $2.08 Million
Q2 2021 Aug 02, 2021	BUY	$135.08 - $161.1 $169,660 - $202,341	1,256 Added 11.92%	11,792 $1.86 Million
Q1 2021 May 21, 2021	BUY	$137.51 - $190.8 $1.45 Million - $2.01 Million	10,536 New	10,536 $1.46 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Beacon Investment Advisory Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Beacon Investment Advisory Services, Inc. with notifications on news.